Login / Signup

Reduced susceptibility to aztreonam-avibactam conferred by acquired AmpC-type β-lactamases in PBP3-modified Escherichia coli.

Nicolas HelsensMustafa SadekChristophe Le TerrierLaurent PoirelPatrice Nordmann
Published in: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2024)
Although none of the recombinant strains tested displayed clinical resistance to aztreonam-avibactam, our data emphasize that the occurrence of such profile might be of clinical relevance for MBL-producing strains.
Keyphrases
  • escherichia coli
  • klebsiella pneumoniae
  • gram negative
  • risk assessment
  • biofilm formation
  • electronic health record
  • big data
  • cell free
  • machine learning
  • pseudomonas aeruginosa
  • cystic fibrosis